"Emerging therapy – Medical science continues to evolve and new therapies are constantly emerging. The oncology field attracts more R&D investment than most and consequently there are many new drugs in the pipeline. Despite this, based on our enquiries there are no late stage drugs in development for the treatment of Pancreatic Cancer. Clinical trials frequently produce good result at the phase II stage of development, however, these often fail to repeat in broader populations across multiple treatment centres. While the threat of an emerging therapy is constant, it is not imminent"
Above from BELL POTTER 0n 14/Nov/2019; Analyst John Hester 612 8224 2871; Tanushree Jain 612 8224 2849 .
You mentioned RFA; IRE(Nanoknife); SABR; HIFU should have no significant effective for pancreatic cancer. Otherwise, Analyst John ad Tanushree should mentioned risks on the emerging therapy. And are you sure IRE CE approved? and IRE is significant effective for pancreatic cancer？ If yes, please give us further information.
From ABC radio ad AGE news on 12/Feb/2020, I understand patients are still waiting advanced solution for pancreatic cancer.
OSL Price at posting:
18.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)